By Nono Hu, Director of Marketing, LSN
With 10 days to go until the first RESI San Diego event, LSN is proud to present the latest RESI program guide. If you want to see the full lineup of sponsors, investor panelists, RESI Innovators and speakers, you’re in the right place. RESI San Diego will bring together hundreds of active investors and early stage startups to begin their BIO week with a dedicated day of partnering, networking, and early stage-focused content. Check out the details below.
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
Life Science Nation (LSN) and Johnson and Johnson Innovation, JLABS have launched San Diego’s first Redefining Early Stage Investments (RESI) Conference on June 19th, 2017 during the 2017 BIO week when the biotech and medtech world gathers in San Diego. RESI San Diego will bring together 400+ fundraising CEOs and 400+ early stage investors (a 1:1 ratio) from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations. Register for RESI now.
By Lucy Parkinson, Director of Research, LSN
RESI is a venue where early stage life science startups can meet with investors of every type that are a fit for their company’s technology and stage – and that includes family offices. RESI San Diego features two panels devoted to this elusive investor class – Biotech Family Offices and Medtech Family Offices. Whether you’re developing a novel therapeutic, an innovative device or an improved diagnostic solution, Family Offices can’t be overlooked as a potential source of capital and RESI will provide you with the opportunity to hear advice and insight directly from key investment decision makers from family offices.
Biotech Family Offices, moderated by Colin Widen (CEO, Boston Innovation Capital), features:
Medtech Family Offices, moderated by Michael Quigley (VP of Market Research, Life Science Nation), features:
To catch this rare opportunity to meet family office investors with a focus on early stage life science investment, register for RESI now.
By Cole Bunn, Senior Research Analyst, LSN
Angel investors are a major force at the earliest stages of financing for life science companies, and can have a great influence in startup development. As many of these individuals have been entrepreneurs and often take an operational role along with an investment, their capital, network and know-how is crucial for energizing a new venture and ensuring that the company has all its ducks in a row as it goes on to grow as a business and raise more capital.
Given the significant differences in the development and financing needs of biotech vs. medtech companies, LSN has two separate sessions which showcase active angles in each space separately.
The Biotech Angels panel will be moderated by Bernie Rudnick, Founder, Mid Atlantic Bio Angels and will feature the following panelists:
The Medtech Angels panel will be moderated by Brian Frenzel, Member, Band of Angels and will feature the following panelists:
These panel sessions will explore general topics such as how angel groups approach an investment opportunity and how best to pitch to/work with an angel investor as well as more specific topics such as how they work with other angel groups and VCs, what to expect in the diligence process, cap table issues and more.
By Lucy Parkinson, Director of Research, LSN
Corporate venture capital funds have been a key pillar of the life science investment community for some time, and at LSN we’ve seen these groups evolving on strategy to keep up with an increasingly competitive investor marketplace. While many pharma firms still use corporate VC as a strategic vehicle for filling pipelines, these firms are increasingly collaborative and keen to be seen as aligned with the interests of entrepreneurs and other investors, as well as those of their parent companies.
At RESI, a panel of 5 top corporate VCs from around the world will explain how their group makes strategic investments in early stage companies, and how a corporate VC relationship can help a startup company get ahead in development and strategic relationships.
Moderated by Rajeev Dadoo (Partner, SR One), the participants are:
Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
LSN is a matching platform for early stage drugs, devices, diagnostics and healthcare IT and those partners who seek to invest in them. LSN has taken 5 years and 25 staff to develop an integrated partnering and funding platform that fulfils a significant unmet need that players in the life science ecosystem have faced – how to find relevant matches and start a dialogue that uncovers a mutual fit that leads to a successful investment transaction. Many of LSN’s global strategic partners have been aided–either directly or indirectly—in enhancing their pipelines and product offerings with this platform. In these cases, LSN acts as key information source, a feeder of technology assets, or as a catalyst for creating and executing opportunities for new revenue channels.
LSN created a fully integrated platform of interrelated products and services that enable buyers (pharma, medical device, equity investors), and sellers (early stage life science companies) to connect based on mutual fit. Using this suite of products and services, LSN can source, vet, rank, package and introduce companies to potential partners with an unrivaled reach in the early stage life science arena. Buyers can find technology assets and sellers can find compelling partners that are a fit for their stage of development and products.
LSN’s integrated product and services can be mixed and matched to fill your firm’s development needs, providing more efficiency to your projects. Be it sourcing, vetting, ranking, introducing partners, creating global road trips, licensing, M&A or equity investment, LSN products can be configured to match any client’s needs.
By Natasha Eldridge, RESI Conference Manager, LSN
RESI Partnering launched on Monday, and the activity level is already incredible. LSN has been collecting and analyzing RESI Partnering data ever since RESI 1 in September 2013. Within our first day post launch, we saw a 30% increase in the number of meeting requests compared to our data from last year. This activity in the system has resulted in the number of confirmed meetings nearly doubling daily since Monday, a testament to the efficiency of the RESI Partnering’s matching capability.
It is exciting to see this kind of growth, especially since this will be the first time RESI will be in San Diego, but this acceleration in meeting requests and confirmations demonstrates the importance of getting on board as soon as possible; as we noted last week, The Early Entrepreneur Gets the Meetings.
Register today because the sooner you are in the RESI Partnering Platform, the greater your chances are to get the best meetings with investors, companies, and strategic partners.
Next Phase Newsletter 